[Combined modality treatment of small cell lung cancer by chemotherapy, radiotherapy, immunotherapy and Chinese traditional medicine].
The combined modality treatment consisted mainly of long-term intermittent combination chemotherapy (VCMB being in the majority) and radiotherapy combined with immunotherapy as well as Chinese traditional medicine. The patients treated with this therapy were observed in 1974-1986, till successive fifty, and followed up to January 1988. They were of the stage I, II, III and IV including 3, 10, 20 and 17 patients respectively. The complete remission rate was 54% (27/50); the partial remission rate, 40% (20/50). The total effective rate was 94% (47/50). According to the calculation of life-table, 2-year survival rate for the stage I-II (n = 13) was 76.2%; 5-year survival rate, 55.5%. For the stage III (n = 20), 2-year survival rate was 46.9%; 5-year, 18.8%. By long-term combined modality, the survival rate has obviously improved, and the possibility of cure has evidently increased.
Cha
R J
RJ
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D002330:Carmustine / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007978:Levamisole / Q000008:administration & dosage; D008175:Lung Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D014750:Vincristine / Q000008:administration & dosage
D004365:Drugs, Chinese Herbal; D007978:Levamisole; D014750:Vincristine; D003520:Cyclophosphamide; D002330:Carmustine; D008727:Methotrexate